22 October 2015 - Meda Canada today announced that Dymista nasal spray (azelastine hydrochloride with fluticasone propionate) has been approved by Health Canada for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either anti-histamines or intranasal corticosteroids is not considered sufficient.

For more details, go to: http://www.newswire.ca/news-releases/good-news-for-allergy-sufferers-dymista-is-approved-by-health-canada-for-the-treatment-of-seasonal-allergic-rhinitis-535901381.html